PCD6: COST ANALYSIS OF ANTIHYPERTENSIVE DRUG USE IN TURKEY  by Sapci, H et al.
Abstracts 69
Managing a patient with a second AMI was 30% more
costly ($34,700 versus $26,600 for single AMI). A stroke
results in a 140% increase ($63,836). Occurrence of any
secondary event increases the first year management
costs by approximately 36% (range: 4% for angina to
149% for CABG). CONCLUSIONS: To properly esti-
mate the cost of AMI, the impact of secondary events
needs to be considered. The increased economic burden
resulting from these secondary events goes beyond the
additional cost of another hospitalization. This informa-
tion should be incorporated into economic models that
address drug therapies for secondary prevention in AMI.
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OBJECTIVES: Recent advances in left ventricular assist
device (LVAD) technology have made this therapy a life-
saving bridge to orthotopic heart transplant (OHT) in
patients with heart failure who fail maximal medical ther-
apy, including positive inotropic support. This study ex-
amined the costs of LVAD versus traditional intravenous
positive inotropic support strategies in patients awaiting
OHT. METHODS: To determine the economic impact
of using either LVAD or positive inotropic support strat-
egies for patients awaiting OHT, we retrospectively ex-
amined the itemized inpatient billing records of all pa-
tients who underwent OHT in 1993 (N  18) and 1996
(N  32) at our center. PreOHT costs (in 1997 US $) were
calculated for each billed item using institutional cost:charge
ratios. Items were categorized as pharmacy, procedure,
laboratory, bed, blood product, respiratory care, and sup-
ply. Professional fees were excluded from the analysis. Per
diem costs were calculated to control for interpatient dif-
ferences in length of stay. RESULTS: LVAD support was
utilized in 10 patients, and the remaining 40 patients re-
ceived only positive inotropic therapy prior to OHT. The
groups were demographically and clinically similar. Pre-
OHT length of stay was 113  63 days vs 71  46 days
(LVAD vs positive inotrope groups; P  0.02). Total pre-
OHT per diem costs were $3651  1510 for LVAD pa-
tients and $2625  602 for positive inotrope patients (P 
0.01). Although per diem pharmacy and bed costs were
similar, costs in the LVAD patients for procedures ($794 
667 vs $237  289), laboratories ($436  280 vs $260 
138), blood products ($122  148 vs $12  16), respira-
tory care ($222  263 vs $61  123), and supplies ($223 
131 vs $141  62) were significantly higher than in posi-
tive inotrope-supported patients (P  0.01 for all). CON-
CLUSIONS: In this study, length of stay and per diem
costs were higher in patients requiring LVAD implanta-
tion as a bridge to transplant. These increased costs may
be justified given the extremely high mortality of these
patients in the absence of LVAD support.
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The ministry of health is preparing a national rational
drug consumption program in Turkey. It is a must to ra-
tionalize drug use and effectively reorganize reimburse-
ment of drugs in order to minimize costs and maximize
effective treatment. However, due to the lack of studies
on drug prescription habits, rational drug prescribing
and cost analysis, it is not possible to make effective
changes. OBJECTIVE: We have conducted a pilot study
on reimbursed prescriptions of Emekli Sandigi and Bag-
Kur from January 1998-between September 1999 and
evaluated antihypertensive drugs. METHODS: 2278 pre-
scriptions from Ankara Numune Hospital and the social
security systems (Emekli Sandigi, Bag-Kur) were chosen
randomly. Medical information included the length of
time medications were extracted. RESULTS: Cost analy-
sis of antihypertensives showed that the average total
cost of antihypertensive treatment was $9.09 (range
$0.89–$30.52) per patient and the most prescribed anti-
hypertensive drug class was ACE inhibitors (25%).
CONCLUSIONS: Taking the results of this pilot study
into consideration, a master study for Turkey is planned
which will also include postgraduate training programs
to enhance rational prescription. In October 1999 the
first program was held in Patalya Hotel-Ankara by the
ministry of health.
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The use of such anti-platelet agents as aspirin and ticlopi-
dine have not been approved in Japan for use in the pre-
vention of the recurrence of cerebrovascular diseases that
include cerebral infarction. Cilostazol is an anti-platelet
agent indicated for the treatment of ischemic symptoms,
including ulcer, pain, and cold sensation in chronic arterial
occlusion, but it also has been confirmed to be effective
over placebo with respect to the prevention of cerebral inf-
arction recurrences through a randomized, double-blind,
placebo controlled, multi-center clinical trial (RCT). OB-
